IFM Investors Pty Ltd Decreases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

IFM Investors Pty Ltd lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,447 shares of the medical research company’s stock after selling 746 shares during the period. IFM Investors Pty Ltd’s holdings in Thermo Fisher Scientific were worth $47,288,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Grimes & Company Inc. boosted its holdings in Thermo Fisher Scientific by 3.2% in the 3rd quarter. Grimes & Company Inc. now owns 2,390 shares of the medical research company’s stock worth $1,479,000 after buying an additional 74 shares during the period. Greystone Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 3.2% in the 3rd quarter. Greystone Financial Group LLC now owns 3,227 shares of the medical research company’s stock worth $1,996,000 after buying an additional 100 shares during the period. Great Lakes Retirement Inc. boosted its holdings in Thermo Fisher Scientific by 2.0% in the 3rd quarter. Great Lakes Retirement Inc. now owns 4,794 shares of the medical research company’s stock worth $2,966,000 after buying an additional 96 shares during the period. Tanager Wealth Management LLP boosted its holdings in Thermo Fisher Scientific by 3.8% in the 3rd quarter. Tanager Wealth Management LLP now owns 1,008 shares of the medical research company’s stock worth $624,000 after buying an additional 37 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 76,051.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company’s stock worth $876,152,000 after buying an additional 1,414,556 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.4 %

Shares of TMO stock traded down $13.58 during mid-day trading on Thursday, reaching $562.91. The stock had a trading volume of 626,777 shares, compared to its average volume of 1,463,755. The stock’s 50-day moving average price is $607.04 and its two-hundred day moving average price is $584.39. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $627.88. The firm has a market capitalization of $215.03 billion, a PE ratio of 35.04, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.15 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at approximately $8,397,760.98. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,084 shares of company stock worth $14,094,292. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on TMO. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday. Finally, Bernstein Bank raised their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $653.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.